TIME TO PSA NADIR AND CANCER RECURRENCE

Med Oncol. 2013 Dec;30(4):719. doi: 10.1007/s12032-013-0719-0. Epub 2013 Sep 12.

Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.

Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, Staffurth J, Tanguay JS, Lester JF.

Source

Velindre Cancer Centre, Velindre NHS Trust, Velindre Road, Whitchurch, Cardiff, CF14 2TL, UK, betsanthomas@doctors.net.uk.

Abstract

Docetaxel has been shown to improve survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). There is no clear consensus regarding the optimum duration of chemotherapy. If patients at greater risk of rapid disease relapse could be identified when on chemotherapy, appropriate follow-up strategies could be put into place. The aim of our study was to find prostate specific antigen (PSA) characteristics that predict a shorter disease response to docetaxel chemotherapy. Data from 41 consecutive mCRPC patients treated with three-weekly docetaxel chemotherapy at a single centre between February 2010 and February 2012 were retrospectively analysed. All patients had ≥50% reduction in their PSA with chemotherapy. The relationship between time to PSA nadir (TTN) and PSA halving time with time to PSA progression and overall chemotherapy response duration was analysed. TTN was a strong predictor of the duration of chemotherapy response and time to PSA progression. When TTN was ≥16 weeks, the mean duration of response to chemotherapy was 37.5 weeks compared to 19.9 weeks when TTN <16 0.63-8.60="" 10="" 12.66-22.60="" 12.8="" 8.2="" a="" an="" and="" chemotherapy="" ci="" duration="" for="" from="" if="" independent="" initiation="" is="" mcrpc="" mean="" observed="" of="" p="" patients="" predictor="" progression-free="" progression="" psa="" response="" shorter="" survival.="" that="" the="" time="" to="" ttn="" was="" we="" weeks="" with="">